What's so special about the Sputnik V vaccine?

In August 2020, Russia became the first country in the world to register a vaccine against COVID-19 (Sputnik V). Up to now, the Sputnik V vaccine is considered to have advantages.

What's so special about the Sputnik V vaccine?
Sputnik V Vaccine

Let's take a look at the development of this vaccine

Sputnik V vaccine has been put into clinical trials in phase 3 (final stage) from August 11, 2020. During this period, more than 16,000 volunteers divided into two groups participated in the trial at 29 medical centers. The trial of the Sputnik V vaccine took place within 21 days.

In September 2020, the vaccine Sputnik V gave results. Accordingly, only about 4% of people vaccinated with flu-like symptoms in a short time such as fever, fatigue, headache, did not detect any abnormal phenomenon. This is a good result that exceeds expectations, confirming that Sputnik V is a highly safe vaccine.

The name Sputnik V was given to the world's first vaccine against Covid-19 with the connotation of a miracle Victory - Victory over Covid.

The Russian Ministry of Health has also published data showing that the country's vaccine Sputnik V against Covid-19 is more than 90% effective. Up to now, more than 70 countries and territories around the world have allowed the use of Sputnik V vaccine in the population vaccination campaign.

The Sputnik V vaccine shows outstanding advantages over other Covid-19 vaccines being used in the world.

The Russian Ministry of Health has also published data showing that the country's vaccine Sputnik V against Covid-19 is more than 90% effective.
The Russian Ministry of Health has also published data showing that the country's vaccine Sputnik V against Covid-19 is more than 90% effective.

The first vaccine against Covid-19 in the world

On August 11, 2020, the press reported that the first vaccine against the SARS-CoV-2 virus called "Sputnik V". The name Sputnik V was given to the world's first vaccine against Covid-19 with the connotation of a miracle Victory - Victory over Covid.

Russia began clinical trials of a vaccine against COVID-19 in June 2020. Less than two months later, President Vladimir Putin announced that the Gamaleya National Research Center for Epidemiology and Microbiology had registered for use. World's first Covid-19 vaccine. vaccine The third phase of the trial started in September 2020 with 40,000 volunteers participating.

Following that, a mass vaccination campaign in Russia was announced in December 2020.

The technology of the Sputnik vaccine is considered safe

The Sputnik V vaccine has a vector mechanism of action. This means it uses a modified version of the virus (which is incapable of replicating) to deliver genetic material into human cells. This makes it a benign virus. After that, the viral vector is added with the gene that produces the spike protein of the SARS-CoV-2 virus and becomes a vaccine. The vector virus itself is safe and cannot make us sick.

When the human body is vaccinated, this vector enters the cell and causes it to produce a mutated protein. As soon as the immune system notices this protein, it begins to produce antibodies and trigger other reactions in the body. So if the body then encounters the SARS-CoV-2 virus, the body already has antibodies to destroy the virus.

On February 2, 2021, a published in the medical journal "The Lancet", the effectiveness of the Sputnik V vaccine was 91.6%, higher than some other vaccines on the market such as Novavax (89%), Johnson & Johnson (66%), Sinovac (50%).

Sputnik V has its own undeniable advantages. Typically, it can be stored at standard temperatures between 2-8 degrees Celsius, while there are vaccines like Pfizer-BioNTech that need to be stored at minus 70 degrees.

The difference between Sputnik V vaccine and other viral vector vaccines is that Sputnik V is a combination vector vaccine, that is, two doses of Sputnik V have two different viral vectors (the first dose uses adenovirus Ad26 and the first dose uses the Ad26 adenovirus and the first dose uses the Ad26 adenovirus). the second uses Ad5).

While other vaccines of the same technology use only one viral vector for both doses. For example, AstraZeneca uses ChAdOx1 virus vector, Johnson & Johnson's Janssen uses Ad26, CanSino's Convidecia uses Ad5.

Sputnik V is a combination vector vaccine, i.e. two doses of Sputnik V containing two different viral vectors.
Sputnik V is a combination vector vaccine, i.e. two doses of Sputnik V containing two different viral vectors.

So in essence, two doses of Spunik V vaccine can be considered two different vaccines or this is a dual vaccine.

Scientists call it a groundbreaking and globally unique combination. According to them, the second injection of a different viral vector vaccine will help the immune system strengthen its ability to better recognize and fight the SARS-CoV-2 virus and variants.

At the same time, this will prolong immunity better than two doses of the same vaccine.

Highly effective in neutralizing the Delta variant

While countries are focusing on researching a vaccine against COVID-19, the SARS-CoV-2 virus is also constantly mutating to create new "dangerous" and "smarter" variants that can resist antibodies. produced by the vaccine.

It is because of this that the creation of a vaccine against COVID-19 really has to take into account the ability to resist variants, especially with the currently overwhelming Delta variant.

The Sputnik V vaccine was also able to protect against 94.37% of severe Delta variant infections that required hospitalization.
The Sputnik V vaccine was also able to protect against 94.37% of severe Delta variant infections that required hospitalization.

In a statement on June 22, 2021, Alexander Gintsburg, head of the Gamaleya Institute of Epidemiology and Microbiology, said that "antibodies developed after vaccination with Sputnik V will effectively protect against variants of the currently prevalent SARS-CoV-2, ranging from the Delta variant first detected in India to those appearing in the United Kingdom."

On August 3, 2021, according to Reuters, Russia's Direct Investment Fund (RDIF) said that the epidemiological efficacy of the Sputnik V vaccine against the Delta variant was 83.1%, which is significantly higher than that of a vaccine. other vaccines. The Sputnik V vaccine was also able to protect against 94.37% of severe Delta variant infections that required hospitalization.

Antibodies developed after vaccination with Sputnik V will effectively protect against variants of the SARS-CoV-2 that are prevalent today.

Alexander Gintsburg, head of the Gamaleya Institute of Epidemiology and Microbiology

Speaking on Russia's Radio 1, Alexander Gintsburg explained the effectiveness of the Sputnik vaccine as follows: "In contrast to the mRNA vaccine that only reacts to one structural state, the Sputnik V vaccine is good because it produces reacts with the spike protein S of the SARS-CoV-2 virus in multiple structural states.

Thus, the mRNA vaccine, while providing a robust immune response, is only against a very limited number of antigenic variants. The Sputnik V vaccine produces a uniform response to a very large number of antigenic variants. This is one of its main advantages."

Antibodies developed after vaccination with Sputnik V will effectively protect against variants of the SARS-CoV-2 that are prevalent today.
Antibodies developed after vaccination with Sputnik V will effectively protect against variants of the SARS-CoV-2 that are prevalent today.

Not only with Delta variant, Sputnik V vaccine has also been shown to be effective against other variants such as Beta, Alpha.

The Sputnik V vaccine was registered in Russia on August 11, 2020, becoming the world's first officially registered COVID-19 vaccine. The export of Sputnik V started at the end of 2020 and has now been approved in more than 70 countries and territories.

Google Tech News

Post a Comment

Previous Post Next Post